Arterra Bioscience (ARBS) Stock Overview
A research-based biotech company, engages in the research and development of various ingredients and natural solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
ARBS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Arterra Bioscience S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.06 |
| 52 Week High | €3.58 |
| 52 Week Low | €1.89 |
| Beta | 0.81 |
| 1 Month Change | 3.38% |
| 3 Month Change | 9.29% |
| 1 Year Change | 59.38% |
| 3 Year Change | 28.57% |
| 5 Year Change | -10.26% |
| Change since IPO | -10.30% |
Recent News & Updates
Recent updates
Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13
Apr 15
Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last Year
Apr 01Arterra Bioscience S.p.A.'s (BIT:ARBS) P/E Is On The Mark
Feb 13A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ARBS)
Aug 03A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ABS)
Jan 09Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)
May 27Shareholder Returns
| ARBS | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 2.0% | -0.9% | 1.5% |
| 1Y | 59.4% | 18.1% | 29.7% |
Return vs Industry: ARBS exceeded the Italian Biotechs industry which returned 18% over the past year.
Return vs Market: ARBS exceeded the Italian Market which returned 31.4% over the past year.
Price Volatility
| ARBS volatility | |
|---|---|
| ARBS Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IT Market | 6.9% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: ARBS's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: ARBS's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Maria Colucci | www.arterrabio.it |
Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. Arterra Bioscience S.p.A. was founded in 2003 and is based in Napoli, Italy.
Arterra Bioscience S.p.A. Fundamentals Summary
| ARBS fundamental statistics | |
|---|---|
| Market cap | €20.37m |
| Earnings (TTM) | €1.34m |
| Revenue (TTM) | €4.17m |
Is ARBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARBS income statement (TTM) | |
|---|---|
| Revenue | €4.17m |
| Cost of Revenue | €1.76m |
| Gross Profit | €2.41m |
| Other Expenses | €1.08m |
| Earnings | €1.34m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 57.85% |
| Net Profit Margin | 32.03% |
| Debt/Equity Ratio | 3.1% |
How did ARBS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 10:11 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arterra Bioscience S.p.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Valentina Romitelli | ValueTrack |